The FDA has tentatively approved Biocon Limited’s (OTC:BCNQY) marketing application for a generic version of AstraZeneca’s (AZN -0.7%) type 2 diabetes med Farxiga (dapagliflozin).
Tentative approval means that Biocon’s marketing application met the requirements for approval, but patent issues need to be resolved before full approval is granted.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.